Progress in antiangiogenic gene therapy of cancer

Cancer

Volumn 89, Issue 6, 2000, Pages 1181-1194

  Feldman, Andrew L ^a   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Angiostatin; Cancer; Endostatin; Gene therapy; Nonviral vectors; Vascular endothelial growth factor (VEGF); Viral vectors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOSTATIN; ANTITHROMBIN; CYTOKINE; ENDOSTATIN; FIBRONECTIN; GENE PRODUCT; INTERFERON; LIPOSOME; MASPIN; PLASMID DNA; PLASMINOGEN ACTIVATOR; PROLACTIN; PROLIFERIN; PROSTATE SPECIFIC ANTIGEN; PROTAMINE; PROTEIN P16; PROTEIN P53; RECOMBINANT PROTEIN; RESTIN; RETINA S ANTIGEN; RETINOIC ACID; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; TROPONIN; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; GENE TARGETING; GENE THERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENE;

ANIMALS; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034666258     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000915)89:6<1181::AID-CNCR1>3.0.CO;2-T     Document Type: Review

References (147)

1. Cancer statistics, 1999
2. Tumor angiogenesis: Therapeutic implications
3. Factors promoting tumor angiogenesis
4. What is the evidence that tumors are angiogenesis dependent?
5. Tumor dormancy in vivo by prevention of neovascularization
6. Two competing influences that may explain concomitant tumor resistance
7. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
8. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
9. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3
10. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth
11. Anti-angiogenic cues from vascular basement membrane collagen
12. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
13. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
14. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
15. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth
16. Disruption of angiogenesis by PEX, a noncatalyric metalloproteinase fragment with integrin binding activity
17. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells
18. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
19. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells
20. Antiangiogenic activity of restin, NC10 domain of human collagen XV: Comparison to endostatin
21. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
22. Interleukin 1 is an autocrine regulator of human endothelial cell growth
23. Inhibition of angiogenesis by interleukin 4
24. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis
25. Inhibition of angiogenesis in vivo by interleukin 12
26. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
27. Interleukin-18 acts as an angiogenesis and tumor suppressor
28. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas
29. Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture
30. Inhibition of endothelial cell proliferation by gamma-interferon
31. Identification of an inhibitor of neovascularization from cartilage
32. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2)
33. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3
34. 3 analogues
35. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth
36. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
37. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells
38. Endothelial Monocyte Activating Polypeptide II (EMAP-II) induces endothelial cell specific apoptosis and may be an inhibitor of tumor angiogenesis
39. Gro-β, a -C-X-C- chemokine is anangiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice
40. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
41. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis
42. Maspin is an angiogenesis inhibitor
43. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity
44. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas
45. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
46. Mutant p53 potentiates protein kinase C induction of vascular endothelial cell growth factor expression
47. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
48. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
49. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein
50. Antiangiogenic activity of prostate-specific antigen
51. Protamine is an inhibitor of angiogenesis
52. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells
53. Identification of soluble forms of the fibroblast growth factor receptor in blood
54. Endothelial cell regulation by transforming growth factor-beta
55. Troponin I is present in human cartilage and inhibits angiogenesis
56. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
57. Inhibition of angiogenesis by thrombospondin-2
58. The angiogenesis inhibitor, Endostatin, does not affect murine cutaneous wound healing
59. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
60. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
61. Relationship between disease-free interval and survival in patients with recurrent melanoma
62. Local recurrences following mastectomy: Support for the concept of tumor dormancy
63. Long-term outcome in women less than 30 years of age with breast cancer
64. The influence of angiogenesis research on management of patients with breast cancer
65. The body as a manufacturer of endostatin
66. Impact of the new biologies on the medical and pharmaceutical sciences
67. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
68. Antiangiogenic gene therapy
69. Gene therapy strategies for tumor antiangiogenesis
70. Antiangiogenic gene therapy
71. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
72. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
73. Regulation of distinct steps of angiogenesis by different angiogenic molecules
74. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
75. Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
76. Human gene marker/therapy clinical protocols
77. Vectors for cancer gene therapy
78. Pharmaceutical perspectives of nonviral gene therapy
79. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
80. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
81. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
82. Inhibition of tumor growth correlates with the expression level of a human angiostatin transgene in transfected B16F10 melanoma cells
83. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
84. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
85. Systemic gene delivery expands the repertoire of effective antiangiogenic agents
86. Mouse endostatin inhibits the formation of lung and liver metastases
87. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
88. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
89. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors
90. Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice
91. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography
92. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce intefferon-β
93. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1
94. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
95. Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo
96. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
97. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
98. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus
99. Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth favor inhibits tumor growth in vivo
100. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
101. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extra-cellular domain of the flt-1 vascular endothelial growth factor receptor
102. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
103. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
104. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2
105. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene
106. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
107. Systemic delivery of antiangiogenic adenovims AdmATF induces liver resistance to metastasis and prolongs survival of mice
108. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
109. Patters and emerging mechanisms of the angiogenic switch during tumorigenesis
110. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
111. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells
112. A simple quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor
113. Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones
114. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
115. The interferons: A biological system with therapeutic potential in viral infections
116. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
117. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 over-expression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro
118. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins
119. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells
120. Development of recombinant adenoviruses that drive high level expression of the human metalloproteinases-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: Characterization of their infection into smooth muscle cells and human MCF-7 adenocarcinoma cells
121. Tissue inhibitor of metalloproteinase expression: A target for gene therapy in renal cell carcinoma
122. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity
123. Endothelial monocyte activating polypeptide II (EMAP-II), a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis
124. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
125. Tumor angiogenesis and endothelial cell modulatory factors
126. Tumor cells secrete a vascular permeability factor which promotes ascites fluid accumulation
127. Vascular permeability factor, an endothelial cell mitogen related to PDGF
128. Molecular and biological properties of the vascular endothelial growth factor family of proteins
129. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
130. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
131. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
132. High affinity VEGF binding and development expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis
133. Inhibition of vascular endothelial cell growth factor activity by and endogenously encoded soluble receptor
134. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer
135. In vivo patters of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis
136. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
137. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
138. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth
139. High-efficiency gene transfer into skeletal muscle mediated by electric pulses
140. Tumor-targeted Salmonella as a novel anticancer vector
141. Antitumor activity of thalidomide in refractory multiple myeloma
142. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
143. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma
144. A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer
145. Cancer Gene Ther
146. Clin Cancer Res